Duration of opiate exposure as a determinant of arterial stiffness and vascular age in male opiate dependence: A longitudinal study

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 2, 2014, Pages 158-167

  Reece, A S ^a   Hulse, G K ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

arterial stiffness; dependence; heroin; human ageing; opiates; vascular ageing

Indexed keywords

BUPRENORPHINE; METHADONE; NALTREXONE; OPIATE; TOBACCO SMOKE;

ADULT; AGING; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EXPOSURE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; OPIATE ADDICTION; PULSE WAVE; RISK FACTOR; SPHYGMOMANOMETER; SYSTOLIC BLOOD PRESSURE; TOBACCO;

ARTERIAL STIFFNESS; DEPENDENCE; HEROIN; HUMAN AGEING; OPIATES; VASCULAR AGEING;

ADULT; AGING; ANALGESICS, OPIOID; BLOOD PRESSURE; CASE-CONTROL STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; OPIOID-RELATED DISORDERS; RISK FACTORS; TIME FACTORS; VASCULAR STIFFNESS;

EID: 84895542963     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12121     Document Type: Article

References (38)

1. Hansson GK,. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 2005; 352: 1685-1695.
2. Wang M, Khazan B, Lakatta EG,. Central arterial aging and angiotensin II signaling. Curr Hypertens Rev, 2010a; 6: 266-281.
3. Wang M, Monticone RE, Lakatta EG,. Arterial aging: a journey into subclinical arterial disease. Curr Opin Nephrol Hypertens, 2010b; 19: 201-207.
4. O'Donnell CJ, Nabel EG,. Genomics of cardiovascular disease. N Engl J Med, 2011; 365: 2098-2109.
5. Sadeghian S, Graili P, Salarifar M, Karimi AA, Darvish S, Abbasi SH,. Opium consumption in men and diabetes mellitus in women are the most important risk factors of premature coronary artery disease in Iran. Int J Cardiol, 2010; 141: 116-118.
6. Sadeghian S, Dowlatshahi S, Karimi A, Tazik M,. Epidemiology of opium use in 4398 patients admitted for coronary artery bypass graft in Tehran Heart Center. J Cardiovasc Surg (Torino), 2011; 52: 140-141.
7. Sadeghian S, Darvish S, Davoodi G, et al,. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil, 2007; 14: 715-717.
8. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L,. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend, 2009; 105: 9-15.
9. Smyth B, Hoffman V, Fan J, Hser YI,. Years of potential life lost among heroin addicts 33 years after treatment. Prev Med, 2007; 44: 369-374.
10. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS,. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell, 2009; 20: 319-327.
11. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ,. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend, 2001; 62: 111-123.
12. Hutchinson MR, Zhang Y, Shridhar M, et al,. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun, 2010; 24: 83-95.
13. Adler MW, Rogers TJ,. Are chemokines the third major system in the brain? J Leukoc Biol, 2005; 78: 1204-1209.
14. Neri S, Bruno CM, Pulvirenti D, et al,. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology, 2005; 179: 700-704.
15. Brunton LL, Lazo JS, Parker KL,. Goodman and Gilman's the pharmacologic basis of therapeutics. In:, Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's the pharmacologic basis of therapeutics. 11th edn, Vol. 1. New York: McGraw Hill, 1-2021, 2006.
16. Csiszar A, Wang M, Lakatta EG, Ungvari Z,. Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol, 2008; 105: 1333-1341.
17. Franceschi C, Bonafe M, Valensin S, et al,. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci, 2000; 908: 244-254.
18. Ginaldi L, Loreto MF, Corsi MP, Modesti M, De Martinis M,. Immunosenescence and infectious diseases. Microbes Infect, 2001; 3: 851-857.
19. Reece AS,. Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. Immun Ageing, 2007a; 4: 6-15.
20. Reece AS,. Relative and age-dependent stimulation of soluble and cellular immunity in opiate dependence. J Addict Med, 2012; 6: 10-17.
21. Yin D, Woodruff M, Zhang Y, et al,. Morphine promotes Jurkat cell apoptosis through pro-apoptotic FADD/P53 and anti-apoptotic PI3K/Akt/NF-kappaB pathways. J Neuroimmunol, 2006; 174: 101-107.
22. Jamison RN, Serraillier J, Michna E,. Assessment and treatment of abuse risk in opioid prescribing for chronic pain. Pain Res Treat, 2011; 2011: 941808.
23. Lakatta EG, Wang M, Najjar SS,. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am, 2009; 93: 583-604. Table of Contents.
24. Reece AS,. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy, 2007b; 2: 35-49.
25. Nichols WW, O'Rourke MF,. McDonald's blood flow in arteries: theoretical, experimental and clinical principals. In:, Nichols WW, O'Rourke MF, eds. McDonald's blood flow in arteries: theoretical, experimental and clinical principals, Vol. 1. London: Hodder Arnold, 2005.
26. Nichols WW,. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens, 2005; 18: 3S-10S.
27. Williams B, Lacy PS, Thom SM, et al,. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 2006; 113: 1213-1225.
28. Gallagher D, Adji A, O'Rourke MF,. Validation of the transfer function technique for generating central from peripheral upper limb pressure waveform. Am J Hypertens, 2004; 17: 1059-1067.
29. Darke S, Kaye S, Duflou J,. Systemic disease among cases of fatal opioid toxicity. Addiction, 2006; 101: 1299-1305.
30. Rosen D, Smith ML, Reynolds CF 3rd,. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry, 2008; 16: 488-497.
31. Cooper OB, Brown TT, Dobs AS,. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis, 2003; 37 (Suppl 2): S132-S136.
32. Kolarzyk E, Pach D, Wojtowicz B, Szpanowska-Wohn A, Szurkowska M,. Nutritional status of the opiate dependent persons after 4 years of methadone maintenance treatment. Przegl Lek, 2005; 62: 373-377.
33. Darke S, Duflou J, Torok M,. The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend, 2010; 106: 1-6.
34. Breslow NE, Day NE, Statistical methods in cancer research volume ii the design and analysis of cohort studies. 1 edn. Lyon: International Agency for Cancer Research, 1987.
35. Reece AS,. Hair graying in substance addiction. Arch Dermatol, 2007c; 143: 116-118.
36. Reece AS,. Differing age related trajectories of dysfunction in several organ systems in opiate dependence. Aging Clin Exp Res, 2011; 24: 85-96.
37. Scuteri A, Orru M, Morrell C, et al,. Independent and additive effects of cytokine patterns and the metabolic syndrome on arterial aging in the SardiNIA study. Atherosclerosis, 2011; 215: 459-464.
38. Le Couteur DG, Lakatta EG,. A vascular theory of aging. J Gerontol A Biol Sci Med Sci, 2010; 65: 1025-1027.